Background & aims: We aimed to develop and evaluate a pathway for
cirrhosis and reduces unnecessary referrals to secondary care of patients with lesser degrees of liver fibrosis. This strategy improves resource use and benefits patients.
Lay summary: Non-alcoholic fatty liver disease effects up to 30% of the population but only a minority of cases develop liver disease. Our study has shown that established blood tests can be used in primary care to stratify patients with fatty liver disease to reduce unnecessary referrals by 80% and improve the detection of cases of advanced fibrosis 5 fold and cirrhosis 3 fold.
Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of deranged liver blood tests (LFTs) in primary care in Europe and North America [1] , and has an estimated prevalence of 25-30% in the adult population [2] . Only a minority of people with NAFLD (5%) develop clinically significant liver disease [2] , but the burden is such that NAFLD is predicted to be the leading indication for liver transplantation within a decade [3] .
The majority of patients with NAFLD are followed up in the community by general practitioners (GPs). Liver fibrosis severity is the key determinant of liver-related outcomes in NAFLD [4] [5] [6] . However, identifying patients with significant fibrosis who might benefit from early specialist intervention is challenging. As clinical assessment is a poor discriminator of fibrosis, such patients progress silently until cirrhosis leads to complications. Accurate fibrosis assessment in primary care is limited by a reliance on LFTs, which correlate poorly with fibrosis [7, 8] and limited access to discriminatory fibrosis tests. Thus current management strategies are inefficient in identifying patients for specialist referral. Patients with mild disease are often referred for specialist review when the appropriate preventative interventions of lifestyle changes can be delivered effectively in primary care [9, 10] . Conversely, patients with advanced fibrosis or cirrhosis who will benefit from specialist interventions including clinical trials and cirrhosis surveillance often remain undetected until they present with cirrhosis complications including hepatocellular carcinoma. This ineffective management contributes to the poor outcomes associated with liver disease and the increasing trends in NAFLD-related morbidity and mortality.
The evolution of non-invasive liver fibrosis tests has created the opportunity for GPs to use these tests in innovative pathways that permit earlier identification of patients with chronic liver disease and subsequent access to specialist care [11] . An example of this approach is outlined in the recent British Society for Gastroenterology guidance on the management of abnormal LFTs that recommends the use of non-invasive tests to stratify patients at risk of CLD [12] .
Whilst there is little evidence supporting the application of non-invasive tests in community settings, with only one study focusing on patients with NAFLD [13] , guidelines recommend a two-tier approach to detect the presence of advanced fibrosis in NAFLD using either FIB-4 or NAFLD Fibrosis score, as an inexpensive first screen, in a combined cut-off approach with indeterminate scores retested using more sensitive and specific tests, ELF™ or FibroScan ® , that are more costly [14] .
Through broad consultation, a care pathway for patients identified with NAFLD in primary care was developed using non-invasive fibrosis assessment (FIB-4 followed by ELF™) to stratify patients to either remain in primary care or to be referred to secondary care. We present a prospective evaluation of the performance of the pathway performed two years after its introduction.
Materials and Methods

Study setting and Design
The Camden and Islington NAFLD Pathway (hereafter the "NAFLD pathway") was developed as a service innovation in conjunction with the primary care were deemed to be at low risk of advanced fibrosis (<F3) and remained in primary care [15] . Primary care management consisted of treatment of cardiovascular risks and diabetes, annual LFTs, and re-assessment of the risk of advanced fibrosis after 3-5 years. Patients with FIB-4>3.25 were deemed to be at high risk of advanced fibrosis and were recommended for referral to secondary care for specialist assessment. Patients with indeterminate FIB-4 values (≥1.30 and <3.25) had second tier testing with an ELF™ test. Patients with ELF™ scores <9.5 were recommended to remain in primary care while those with an ELF™ score ≥9.5 were recommended for referral to secondary care [16, 17] . 
Pathway evaluation:
Following introduction of the NAFLD pathway, data were collected on the outcomes of NAFLD referrals for patients seen at the secondary care sites.
The CCG of the referral origin and use of the NAFLD pathway or Standard Care were recorded. The primary care electronic patient record systems (EMISWeb, Egton Medical Information Systems) were interrogated centrally to obtain data on NAFLD diagnosis and use of the pathway to stratify patients for referral using READ codes in primary care. Secondary care electronic medical records were interrogated to extract data related to patient demographics, secondary care management, fibrosis staging and clinical events.
The diagnostic performance of the NAFLD pathway in detecting cases of advanced fibrosis was assessed against a reference standard composite clinical evaluation performed by expert hepatologists blind to the use of the NAFLD pathway, as described above. All decisions were reviewed by the study team (AS and WMR) and any differences of opinion between the experts and the study team (<10% of cases) were resolved through discussion. Table 1 ).
Secondary
The distribution of FIB-4 scores in patients assessed by C&I GPs before and after introduction of the pathway was compared to look for evidence of bias in patient selection.
Outcomes
The primary outcome was the reduction in the proportion of patients with NAFLD referred to secondary care who did not have evidence of advanced fibrosis based on clinical evaluation and were thus deemed to have been referred unnecessarily.
Secondary outcomes included:
 The number of cases and proportion of those referred who were deemed to have advanced fibrosis or cirrhosis after assessment by a liver specialist (true positive rate).
 Proportion of patients diagnosed with NAFLD avoiding referral after primary care stratification.
 Number of patients coded for NAFLD by GP before and after introduction of the pathway.
Sensitivity analyses were conducted to determine the impact of using agespecific cut-offs for FIB-4 to triage patients [18] . The impact of using alternative ELF™ cut-offs for detection of advanced fibrosis was investigated including the manufacturer's recommendation (ELF™=9.8) and the threshold recommended in recent NICE guidance on NAFLD (ELF™=10.51) [19] .
In order to determine the effectiveness of the pathway compared to Standard Care, the outcomes of patients referred using the NAFLD pathway were compared to those of patients referred from C&I prior to introduction of the pathway; and to those of patients referred using Standard Care from C&I and from other CCGs during the evaluation period following introduction of the pathway.
In order to determine the effectiveness of the introduction of the pathway to all general practices across the two CCGs of C&I, outcomes for all patients referred from C&I, irrespective of the use of the NAFLD pathway, were compared to those of patients referred from all other CCGs where the pathway was not introduced during the evaluation period.
Statistical Analyses
Statistical analyses were performed using SPSS (version 22, SPSS Inc., Chicago, IL, USA). The odds ratios for differences in outcomes for patients managed in accordance with the pathway and those managed using Standard Care were calculated, along with 95% confidence intervals and chi-square tests for statistical significance using Medcalc statistical software (MedCalc Software 2018).
Ethical Approval:
The Royal Free London NHS Foundation Trust Research and Development Department judged this study to be an evaluation of a service improvement innovation, therefore this was registered for audit (EDGE ID:122031) but not subject to review by an independent ethics committee and individual patient consent was not sought. All activities were performed in accordance with the guidelines of the Helsinki Declaration.
RESULTS
Participants:
Between 01/03/2014 and 31/05/2016 in C&I CCGs, 3,012 patients were coded as having NAFLD, with an equal distribution in the numbers entered into the NAFLD pathway and Standard Care (Table 1) . Seventy-two per cent of eligible practices (52/72) used the NAFLD pathway to stratify a proportion of their patients. Patients entered into the NAFLD pathway compared to Standard Care were older (54.4 years vs. 51.5, P<0.001), had a higher prevalence of treated type 2 diabetes (27.6% vs. 21.0%, P<0.001) and hypertension (41.7% vs. 33.0%, P<0.001), and less dyslipidaemia (13.5% vs. 14.6%, P<0.001).
There were no significant differences in Q-Risk2 score, HbA1c, transaminases, platelet counts or HDL. The distribution of calculated FIB-4 scores in 695 cases for which the data were available was identical between the patients managed using the NAFLD pathway and those managed using Hepatologists diagnosed more cases of cirrhosis amongst patients referred using the NAFLD pathway compared to those referred by C&I GPs using Standard Care (22/152 (14.5%) compared to 10/177 (5.6%)). This equates to nearly a 3-fold improvement in the detection of cases of cirrhosis (OR=2.83; 95%CI=1.29-6.18; p=0.009). The number of referrals required to detect one case of advanced fibrosis was 3.4 using the pathway compared to 12.6 using Standard Care.
Comparison of the NAFLD pathway with Standard Care provided by other CCGs during the evaluation period revealed similar results to those observed when comparing the pathway and Standard Care used by GPs within C&I (see Table 3 and Supplementary Data).
Referrals made from Camden and Islington Before and After
Introduction of the NAFLD Pathway
Due to the increased awareness of NAFLD in 2014-16 compared to 2012-13, rates of referral to secondary care were analysed proportionate to the number of contemporaneously coded NAFLD cases, rather than comparing the absolute numbers of cases referred and detected per year.
Prior to the pathway introduction in one year 79/83 (95.2%) referrals made to secondary care were deemed unnecessary. Following introduction of the NAFLD pathway over a period of 2 years, the number of unnecessary referrals fell to 107/152 (70.4%) representing an 88% reduction when the pathway was followed (OR=0.12; 95%CI=0.042-0.349; p<0.0001) ( Tables   2,3 There were no statistically significant differences in the outcomes for patients managed using Standard Care before or after introduction of the pathway suggesting that there was no Hawthorne or bystander effect [20] from diffusion of the benefits of the pathway to patients managed using Standard Care.
The impact of using age-adjusted FIB-4 thresholds
Subsequent to the design and implementation of the NAFLD pathway the influence of age on FIB-4 was investigated, leading to a recommendation to adjust the threshold of FIB-4 score in people aged over 65 [18] . While adopting this higher threshold would have reduced the number of unnecessary referrals to secondary care by 29 from 122 to 93, (23% reduction), this would result in the loss of 12 cases with advanced fibrosis of which 4 had cirrhosis ( Table 2) .
Modelling of the impact of other ELF™ Thresholds
The effect of using the ELF threshold proposed by NICE (10.51) [19] and the manufacturers of ELF (9.8) [21] rather than the threshold selected by the NAFLD pathway working group was investigated in the referral population (Table 4) . Employing a threshold of 9.8 would have avoided 11 (7.2%) unnecessary referrals but with a concomitant loss of 3 (6.7%) cases of The NAFLD pathway working group elected to use blood tests to stratify liver fibrosis severity rather than transient elastography that has been used in other successful pathways [23] . Blood tests have the advantages that they are easily incorporated into routine investigations in primary care, require no specialist equipment, training or operation and have a lower diagnostic failure rate compared to elastography-based methods including FibroScan®, which has failure rates between 5-15% of cases, especially in NAFLD [24] . Following introduction of the pathway, only 19% of cases of NAFLD diagnosed in primary care were deemed suitable for referral to secondary care. Although not appropriate to compare this proportion with referral practice prior to the pathway introduction, it is noteworthy that using the same criteria, 93% of patients referred to secondary care prior to the pathway introduction were judged to have been unnecessary.
The beneficial effects of the pathway were restricted to cases that followed the pathway. During the evaluation period, despite evidence of improved awareness of NAFLD, suggested by increased coding of NAFLD, there was no evidence of improvement in case detection or any reduction in unnecessary referrals when Standard Care was followed rather than the pathway. This demonstrates the value of use of the pathway but also shows that there was no diffusion of the pathway benefits to patients managed with Standard Care or any significant change in "standard" practice due to emerging awareness of NAFLD during the evaluation period.
Only 48% of referrals from C&I were made using the NAFLD pathway. Prior to introduction of the NAFLD pathway, funders expressed concern that the pathway might lead to a marked increase in referrals to secondary care leading to greater costs. Despite an increase in the diagnosis of NAFLD between 2012-2016 denoted by the increase in the coding of patients for NAFLD, use of the pathway resulted in a 3% reduction in the proportion of NAFLD cases that were referred to secondary care per year whether or not the pathway was followed and only a modest increase in the number of patients referred.
The strengths of this study include the prospective collection of real world data, the size of the cohort, which is the largest primary UK cohort with regards to NAFLD, and the engagement of appropriate stakeholders in the pathway design.
The limitations mostly stem from the nature of the implementation design, which was designed to evaluate a health service innovation. It was not possible to conduct a randomized controlled trial because of the commitment to adopt the pathway once it was discussed with GPs and public health clinicians who formed the opinion that there was sufficient evidence to implement the pathway without a trial. This view was subsequently endorsed by NICE in the NAFLD Guidance 24 .
The NAFLD pathway evaluation lacked a hard outcome measure of liver fibrosis and rather used the composite clinical judgement of an expert clinician blinded to the pathway use. The secondary care evaluation of the included patients thus reflects real world practice, with an inevitable degree of selection bias in the patients undergoing liver biopsy.
Similarly the lack of formal evaluation of the prevalence of fibrosis amongst patients allocated to remain in primary care prevented assessment of the "false negative" rate for the pathway allocation. However longer term follow-up for clinical outcomes and more detailed health economic analyses will reveal the clinical impact of stratification and the true cost effectiveness of the pathway. Patient and service provider acceptance is being gathered and will be reported in due course.
Conclusions
The Camden and Islington NAFLD pathway improved the selection of patients with advanced fibrosis and cirrhosis for referral to secondary care, reducing unnecessary referrals. This in turn delivers improvements in the detection of serious liver damage, better use of healthcare resources and immediate cost savings. The reduction in referrals to secondary care reduces strain on services that are confronting a rising prevalence of obesity and NAFLD as well as benefitting patients' experiences by avoiding unnecessary clinic appointments and investigations. This is the first study to incorporate the BSG guidance on the management of NAFLD and validates the recommendation to use FIB-4 and ELF™ for two-stage stratification. The NAFLD pathway is highly generalizable, as GPs will have access to both FIB-4 and ELF tests through most biochemistry laboratories.
It remains to be seen if the use of the NAFLD pathway delivers benefits in terms of a reduction in the incidence and complications of NAFLD cirrhosis. 

In the face of a growing burden of NAFLD established this pathway can be used in primary care to differentiate those patients who might benefit from referral to liver specialists from those who can be managed safely in primary care.
This should reduce unnecessary referrals while at the same time improving the detection of cirrhosis, improving patient care and healthcare resource use.
